1228948-05-7 Usage
General Description
Tert-Butyl 1-(oxetan-3-yl)piperidin-4-ylcarbamate is a chemical compound that belongs to the class of carbamate derivatives. It is synthesized by reacting tert-butyl isocyanate with 3-oxetanamine, resulting in the formation of a piperidinylcarbamate. tert-Butyl 1-(oxetan-3-yl)piperidin-4-ylcarbamate has potential applications in the field of pharmaceuticals and agrochemicals, as well as in the synthesis of other organic compounds. Its unique structure and properties make it a valuable intermediate in the production of various chemical products. Furthermore, its diverse range of potential applications makes it an interesting target for further research and development in the chemical industry.
Check Digit Verification of cas no
The CAS Registry Mumber 1228948-05-7 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,2,2,8,9,4 and 8 respectively; the second part has 2 digits, 0 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 1228948-05:
(9*1)+(8*2)+(7*2)+(6*8)+(5*9)+(4*4)+(3*8)+(2*0)+(1*5)=177
177 % 10 = 7
So 1228948-05-7 is a valid CAS Registry Number.
1228948-05-7Relevant articles and documents
Bcl-2 INHIBITORS
-
Paragraph 0565; 0566; 0567, (2019/11/19)
Disclosed herein is a compound of Formula (I) for inhibiting Bcl-2 and treating disease associated with undesirable bcl-2 activity (Bcl-2 related diseases), a method of using the compounds disclosed herein for treating dysregulated apoptotic diseases including cancers and treating autoimmune disease, and a pharmaceutical composition comprising the same.
1, 7 - DIAZACARBAZOLES AND THEIR USE IN THE TREATMENT OF CANCER
-
Page/Page column 97, (2011/07/07)
The invention relates to 1, 7-diazacarbazole compounds of Formula (I), (I-a) and (I-b) which are useful as kinase inhibitors, more specifically useful as checkpoint kinase 1 (chk 1) inhibitors, thus useful as cancer therapeutics. The invention also relates to compositions, more specifically pharmaceutical compositions comprising these compounds and methods of using the same to treat various forms of cancer and hyperproliferative disorders, as well as methods of using the compounds for in vitro, in situ, and in vivo diagnosis or treatment of mammalian cells, or associated pathological conditions.
